LACTOLOGY FOUNDATION

A07XA01 Albumin Tannate: Toxicological and Lactological Monograph

ATC Class and General Pharmacology

Albumin tannate (also termed tannin albuminate) is classified in the WHO Anatomical Therapeutic Chemical system as A07XA01, within A07XA, Other antidiarrheals. The WHO Collaborating Centre assigns a defined daily dose of 3 g by the oral route.atcddd.fhi

Albumin tannate is an orally administered astringent antidiarrhoeal preparation formed through association of tannic acid with protein material. Its therapeutic effect is predominantly local within the gastrointestinal tract. Tannins can bind proteins and other macromolecules through hydrogen bonding and hydrophobic interactions, promoting protein precipitation and formation of a protective, astringent layer over an inflamed intestinal mucosal surface. This process may reduce mucosal irritation, diminish excessive secretion of water into the intestinal lumen, and improve stool consistency.journals.sagepub

The medicine is used for symptomatic relief of acute, uncomplicated diarrhoea. It does not provide oral rehydration, antimicrobial eradication, or treatment of the underlying cause of diarrhoea. Its role is therefore supportive and should be integrated with oral fluid and electrolyte replacement where indicated.

The local mechanism is clinically relevant in lactation pharmacology: the degree of maternal systemic absorption is expected to be limited when the product remains predominantly within the intestinal lumen. Nevertheless, albumin tannate should not be assumed to have identical properties to other tannin-containing or protein–tannin complexes, because formulation, tannin source, dose, particle size, excipients, and co-administered ingredients can influence gastrointestinal behaviour and systemic availability.

Toxicological Profile

The toxicological profile of albumin tannate is primarily characterised by gastrointestinal and formulation-dependent considerations. With short-term therapeutic oral use, systemic toxicity is expected to be limited when absorption remains minimal. The principal potential adverse effects are generally local and may include constipation, abdominal discomfort, nausea, altered stool frequency, or excessive reduction in stool liquidity.

Tannins have broad binding capacity and may interact with proteins, mucins, alkaloids, polysaccharides, and certain dietary constituents. This astringent action supports the intended local effect but can also create the potential for reduced absorption of concurrently administered oral medicines, nutrients, or minerals. A practical precaution is to separate albumin tannate from other oral medicines when clinically feasible, particularly medicines with a narrow therapeutic index or those requiring reliable gastrointestinal absorption.

Toxicological uncertainty increases in the following situations:

• High-dose, prolonged, or repeated administration.
• Severe gastrointestinal inflammation, mucosal injury, or increased intestinal permeability.
• Significant renal or hepatic impairment.
• Concurrent use of multiple oral drugs.
• Use in very young children, frail older adults, or patients with severe malnutrition.
• Use of combination products containing other pharmacologically active substances.
• Suspected hypersensitivity to protein-derived or formulation-related constituents.

Albumin tannate should not delay medical evaluation of diarrhoea accompanied by blood in stool, high fever, severe abdominal pain, persistent vomiting, pronounced dehydration, reduced urine output, systemic illness, or symptoms that do not improve within an appropriate short interval. Suppression of stool frequency does not correct the underlying fluid and electrolyte deficit, and rehydration remains central to management.

Lactation Pharmacology and Infant Exposure

There are no robust published human milk concentration studies, relative infant dose calculations, or controlled infant outcome datasets specifically establishing the transfer of albumin tannate into breast milk. Accordingly, the lactation evidence base is limited, and any safety assessment must combine the available evidence with pharmacokinetic plausibility.

Albumin tannate is expected to have low maternal systemic exposure because its therapeutic effect is mainly local within the gastrointestinal tract. Low maternal plasma availability is ordinarily associated with limited transfer into breast milk. In addition, its protein–tannin complex nature and likely low oral bioavailability may reduce the probability that any very small amount reaching milk would be absorbed to a clinically meaningful extent by the infant.

This conclusion is theoretical rather than directly demonstrated. Maternal systemic absorption may be altered by dose, formulation, gastrointestinal inflammation, mucosal injury, prolonged use, or an abnormal gastrointestinal barrier. Formulation-specific characteristics are especially important because commercially available products may differ in tannin source, protein carrier, excipients, and use in combination with other active ingredients.

The theoretical infant exposure is expected to be lowest when albumin tannate is used:

• As a single-ingredient oral product.
• At standard therapeutic doses.
• For a short course.
• By a clinically well and adequately hydrated breastfeeding mother.
• In a term, healthy infant with normal gastrointestinal and renal function.

More cautious assessment is appropriate for premature infants, neonates, infants with gastrointestinal disease, impaired renal or hepatic function, poor feeding, dehydration, or significant concurrent medication exposure. In these circumstances, even low and uncertain exposure warrants greater clinical vigilance.

Lactological Safety Assessment and Clinical Recommendations

Albumin tannate can be provisionally considered a low expected lactation-exposure medicine, particularly for short-term maternal use, because of its predominantly local intestinal action and anticipated limited systemic absorption. However, its classification should remain evidence-limited, since direct measurements in human milk and well-documented infant follow-up data are lacking.

Breastfeeding interruption is generally not expected to be necessary when a healthy lactating patient uses a standard short course of a single-ingredient albumin tannate preparation for uncomplicated diarrhoea. Clinical management should focus on the underlying maternal illness, hydration, hygiene, formulation review, and infant-specific vulnerability.

Recommended clinical approach:

1. Prioritise maternal rehydration. Use oral fluids and electrolyte replacement as needed. Albumin tannate is adjunctive symptomatic treatment and is not a substitute for oral rehydration therapy.
2. Confirm an appropriate indication. Consider other causes of diarrhoea, including infection, medicine-related diarrhoea, inflammatory disease, food intolerance, and chronic gastrointestinal pathology.
3. Use the lowest effective dose for the shortest duration. Avoid extended self-treatment or high-dose administration without medical reassessment.
4. Prefer a single-ingredient, standardised formulation. Review the exact product label. Lactation safety cannot be extrapolated to preparations combined with antiseptics, antimicrobials, minerals, adsorbents, herbal products, or other antidiarrhoeal agents.
5. Separate from essential oral medicines when prudent. Because tannins may bind gastrointestinal compounds, administration at a different time from other orally administered medicines can reduce the potential for impaired absorption.
6. Continue breastfeeding when the mother is clinically stable. Acute uncomplicated maternal diarrhoea alone is not generally an indication to stop breastfeeding. Rigorous hand hygiene and safe food handling are particularly important when infectious gastroenteritis is possible.
7. Monitor the infant pragmatically. Observe for poor feeding, vomiting, unusual constipation or altered stooling, abdominal distension, irritability, lethargy, reduced urine output, or poor weight gain. These signs are nonspecific but warrant paediatric assessment if clinically significant.
8. Escalate care for red flags. Urgent maternal review is appropriate for high fever, blood in stool, severe abdominal pain, inability to retain fluids, signs of dehydration, reduced urine output, severe weakness, or persistent diarrhoea. Seek specialist lactation or paediatric advice when treatment is prolonged, the product is a combination formulation, or the breastfed infant is premature or medically vulnerable.